Marker Therapeutics Inc (MRKR)

[rwwest]

Don't forget that not only Marker but many Bio companies have been slowed in their work by the incredible focus of attention and resources on Covid. This was Peter on May 11-

“While we are eager to initiate our planned Phase 2 trial with our novel MultiTAA-specific T cell therapy in patients with acute myeloid leukemia (AML), we anticipate that the initiation of our trial will be delayed by the impacts the COVID-19 pandemic has had on our clinical trial partners and throughout our supply chain. As a result of the uncertainty, we believe it is prudent to withdraw our prior guidance on the timing of this trial until the outlook clarifies,” said Peter L. Hoang, President & CEO of Marker Therapeutics.